Profound Medical Corp
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping… Read more
Profound Medical Corp (PROF) - Total Assets
Latest total assets as of September 2025: $42.30 Million USD
Based on the latest financial reports, Profound Medical Corp (PROF) holds total assets worth $42.30 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Profound Medical Corp - Total Assets Trend (2014–2024)
This chart illustrates how Profound Medical Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Profound Medical Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Profound Medical Corp's total assets of $42.30 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.2% |
| Accounts Receivable | $7.04 Million | 10.0% |
| Inventory | $5.80 Million | 8.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $261.00K | 0.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Profound Medical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Profound Medical Corp's current assets represent 98.3% of total assets in 2024, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 78.2% of total assets in 2024, down from 100.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 10.0% of total assets.
Profound Medical Corp Competitors by Total Assets
Key competitors of Profound Medical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Profound Medical Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Profound Medical Corp generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Profound Medical Corp is currently not profitable relative to its asset base.
Profound Medical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.18 | 6.12 | 20.32 |
| Quick Ratio | 3.34 | 5.16 | 19.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $31.59 Million | $ 34.21 Million | $ 118.25 Million |
Profound Medical Corp - Advanced Valuation Insights
This section examines the relationship between Profound Medical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.45 |
| Latest Market Cap to Assets Ratio | 2.41 |
| Asset Growth Rate (YoY) | 59.8% |
| Total Assets | $70.23 Million |
| Market Capitalization | $169.46 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Profound Medical Corp's assets at a significant premium ( 2.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Profound Medical Corp's assets grew by 59.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Profound Medical Corp (2014–2024)
The table below shows the annual total assets of Profound Medical Corp from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $70.23 Million | +59.78% |
| 2023-12-31 | $43.96 Million | -31.77% |
| 2022-12-31 | $64.42 Million | -25.66% |
| 2021-12-31 | $86.66 Million | -17.15% |
| 2020-12-31 | $104.60 Million | +249.97% |
| 2019-12-31 | $29.89 Million | -12.55% |
| 2018-12-31 | $34.18 Million | +54.15% |
| 2017-12-31 | $22.17 Million | +25.77% |
| 2016-12-31 | $17.63 Million | +15.44% |
| 2015-12-31 | $15.27 Million | +938.08% |
| 2014-12-31 | $1.47 Million | -- |